• Special Issue Topic

    The Implementation of Liquid Biopsy in Clinical Practice for Different Solid Tumor

    Submission Deadline: May 20, 2022

    Guest Editors

    Dr. Erika Martinelli E-Mail

    Associate Professor in Medical Oncology, Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy

    Research Keywords: colorectal cancer; translational research; resistance to targeted therapies; gastrointestinal cancer

    Dr. Giulia Martini E-Mail

    University of Campania “Luigi Vanvitelli”, Naples, Italy

    About the Special Issue

    This special issue is dedicated to the implementation of liquid biopsy in clinical practice for different solid tumors. Nowadays, tissue genotyping represents a major challenge in oncology due the limit to not completely catch the complex molecular pattern of heterogeneous tumors and the invasiveness and costs of techniques that often limit a fully understanding of cancer landscape along the course of tumor disease. Liquid biopsy analysis has the potential to overcome tumor-biopsy limitations allowing to a longitudinal, comprehensive, and non-invasive monitoring of disease. Remarkably, circulating tumor DNA analysis has the potential to guide treatment decision, monitor response and early catch treatment resistance. Moreover, liquid biopsy analysis has been recently used for the detection of minimal residual disease (MRD), which reflects the presence of tumor cells left after surgery or local treatment or disseminated from the primary tumor in patients with no sign of clinical or radiological progression. 

    The aim of this special issue is to collect original translational research data on the discovery of new blood-based cancer biomarkers and updated reviews of the literature to highlight recent discoveries in the field of precision medicine.

    Keywords: Precision medicine; liquid biopsy; circulating tumor DNA; biomarker; treatment resistance

    Call for Papers

    Published Articles

    Open Access
    Clinical relevance of circulating tumor DNA in ovarian cancer: current issues and future opportunities
    Ovarian cancer (OC) is the most lethal gynecologic malignancy worldwide. Due to the lack of effective screening and early detection strategies, many patients with OC are diagnosed with advanced dise [...] Read more.
    Elena Trevisi ... Ilaria Colombo
    Published: June 19, 2024 Explor Target Antitumor Ther. 2024;5:627–640
    DOI: https://doi.org/10.37349/etat.2024.00239
    Times Cited: 0
    Open Access
    Original Article
    Chemotherapy related changes in cfDNA levels in squamous non-small cell lung cancer: correlation with symptom scores and radiological responses
    Aim: There is limited data on prognostic value of baseline plasma cell free DNA (cfDNA) in advanced squamous non-small cell lung cancer (sq-NSCLC). This prospective observational study aimed to a [...] Read more.
    Nithiyanandan Ravi ... Navneet Singh
    Published: May 28, 2024 Explor Target Antitumor Ther. 2024;5:508–521
    DOI: https://doi.org/10.37349/etat.2024.00232
    Times Cited: 0
    Open Access
    Original Article
    Liquid biopsy: an examination of platelet RNA obtained from head and neck squamous cell carcinoma patients for predictive molecular tumor markers
    Aim: Recently, a tumor cell-platelet interaction was identified in different tumor entities, resulting in a transfer of tumor-derived RNA into platelets, named further “tumor-educated platelets [...] Read more.
    Lisa T. Huber ... Cornelia Brunner
    Published: June 30, 2023 Explor Target Antitumor Ther. 2023;4:422–446
    DOI: https://doi.org/10.37349/etat.2023.00143
    Open Access
    Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer
    Liquid biopsy is a diagnostic repeatable test, which in last years has emerged as a powerful tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring oncological decisi [...] Read more.
    Vincenza Caputo ... Stefania Napolitano
    Published: February 28, 2023 Explor Target Antitumor Ther 2023;4:102–138
    DOI: https://doi.org/10.37349/etat.2023.00125
    Open Access
    Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment
    Recently, technological advances in the detection and biological characterization of circulating tumor DNA (ctDNA) have enabled the implementation of liquid biopsy testing into clinical practice. Me [...] Read more.
    Yoshiharu Sato
    Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:630–642
    DOI: https://doi.org/10.37349/etat.2022.00104
    Open Access
    Clinical applications of liquid biopsy in HPV-negative and HPV-positive head and neck squamous cell carcinoma: advances and challenges
    Head and neck squamous cell carcinomas (HNSCCs) represent the most common epithelial tumors that arise from mucosa of the oral cavity, pharynx, and larynx. The development of HNSCCs is usually assoc [...] Read more.
    Mariana Chantre-Justino ... Lucas Delmonico
    Published: August 31, 2022 Explor Target Antitumor Ther. 2022;3:533–552
    DOI: https://doi.org/10.37349/etat.2022.00099
    Open Access
    Liquid biopsy in biliary tract cancer from blood and bile samples: current knowledge and future perspectives
    Biliary tract cancer (BTC) is an aggressive tumor characterized by a poor prognosis. In the latest years, targetable genetic alterations have been discovered in BTC patients, leading to the approval [...] Read more.
    Gianluca Arrichiello ... Emilio Francesco Giunta
    Published: June 22, 2022 Explor Target Antitumor Ther. 2022;3:362–374
    DOI: https://doi.org/10.37349/etat.2022.00087